Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 278-282

  Song, Si Yeol ^a   Jeong, Seong Yun ^a   Park, Heon Joo ^b   Park, Seung Il ^a   Kim, Dong Kwan ^a   Kim, Yong Hee ^a   Shin, Seong Soo ^a   Lee, Sang wook ^a   Ahn, Seung Do ^a   Kim, Jong Hoon ^a   Lee, Jung Shin ^a   Choi, Eun Kyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

C609T polymorphisms; Local control; Non small cell lung cancer; NQO1; Postoperative; Radiation therapy

Indexed keywords

CISPLATIN; CYTOSINE; NAVELBINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THYMIDINE;

ADJUVANT THERAPY; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ESOPHAGITIS; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LINEAR ACCELERATOR; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; SOUTH KOREA; THORACOTOMY; TREATMENT FAILURE; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PNEUMONECTOMY; POLYMORPHISM, GENETIC; POSTOPERATIVE CARE; PROGNOSIS; RADIOGRAPHY, THORACIC; RADIOTHERAPY, ADJUVANT; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 77950457673     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.009     Document Type: Article

References (42)

1. Group TLLCS Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung. Ann Surg 1987, 205:67-71.
2. Martini N., Yellin A., Ginsberg R.J., Bains M.S., Burt M.E., McCormack P.M., et al. Management of non-small cell lung cancer with direct mediastinal involvement. Ann Thorac Surg 1994, 58:1447-1451.
3. Dautzenberg B., Arriagada R., Chammard A.B., Jarema A., Mezzetti M., Mattson K., et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 1999, 86:265-273.
4. Stephens R.J., Girling D.J., Bleehen N.M., Moghissi K., Yosef H.M., Machin D. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 1996, 74:632-639.
5. Feld R., Rubinstein L., Thomas P.A. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 1993, 85:299-306.
6. Lin P., Hsueh Y.M., Ko J.L., Liang Y.F., Tsai K.J., Chen C.Y. Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer 2003, 40:123-129.
7. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44:311-316.
8. Simon G.R., Sharma S., Cantor A., Smith P., Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127:978-983.
9. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
10. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995, 49:127-140.
11. O'Brien P.J. Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 1991, 80:1-41.
12. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000, 129:77-97.
13. Tudor G., Gutierrez P., Aguilera-Gutierrez A., Sausville E.A. Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression. Biochem Pharmacol 2003, 65:1061-1075.
14. Asher G., Lotem J., Kama R., Sachs L., Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 2002, 99:3099-3104.
15. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA 2001, 98:1188-1193.
16. Siegel D., Gibson N.W., Preusch P.C., Ross D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990, 50:7293-7300.
17. Siegel D., Gibson N.W., Preusch P.C., Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990, 50:7483-7489.
18. Walton M.I., Smith P.J., Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2.DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 1991, 3:199-206.
19. Kasahara K., Shibata K., Bando T., Numata Y., Fujimura M., Matsuda T. DT-diaphorase as a determinant of sensitivity to adriamycin in non-small-cell lung-cancer cell lines. Int J Cancer 1994, 59:204-207.
20. Beall H.D., Hudnott A.R., Winski S., Siegel D., Swann E., Ross D., et al. Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1. Bioorg Med Chem Lett 1998, 8:545-548.
21. Belinsky M., Jaiswal A.K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993, 12:103-117.
22. Hamajima N., Matsuo K., Iwata H., Shinoda M., Yamamura Y., Kato T., et al. NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002, 7:103-108.
23. Lind C., Cadenas E., Hochstein P., Ernster L. DT-diaphorase: purification, properties, and function. Methods Enzymol 1990, 186:287-301.
24. Riley R.J., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 1992, 43:1657-1669.
25. Jaiswal A.K. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med 2000, 29:254-262.
26. Radjendirane V., Joseph P., Jaiswal A. Gene expression of DT diaphorase (NQO1) in cancer cells. Oxidative Stress and Signal Transduction 1997, Chapman & Hall, New York, pp. 441-475.
27. Choi E.K., Terai K., Ji I.M., Kook Y.H., Park K.H., Oh E.T., et al. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 2007, 9:634-642.
28. Chen H., Lum A., Seifried A., Wilkens L.R., Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 1999, 59:3045-3048.
29. Lin P., Wang H.J., Lee H., Lee H.S., Wang S.L., Hsueh Y.M., et al. NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health A 1999, 58:187-197.
30. Lewis S.J., Cherry N.M., Niven R.M., Barber P.V., Povey A.C. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 2001, 34:177-183.
31. Menzel H.J., Sarmanova J., Soucek P., Berberich R., Grunewald K., Haun M., et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 2004, 90:1989-1994.
32. Anwar A., Siegel D., Kepa J.K., Ross D. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone oxidoreductase 1. J Biol Chem 2002, 277:14060-14067.
33. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H., Danenberg P.V., Ross D., et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992, 52:797-802.
34. Traver R.D., Siegel D., Beall H.D., Phillips R.M., Gibson N.W., Franklin W.A., et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997, 75:69-75.
35. Siegel D., McGuinness S.M., Winski S.L., Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999, 9:113-121.
36. Ross D., Traver R.D., Siegel D., Kuehl B.L., Misra V., Rauth A.M. A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 1996, 74:995-996.
37. Kuehl B.L., Paterson J.W., Peacock J.W., Paterson M.C., Rauth A.M. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 1995, 72:555-561.
38. Agrawal A., Choudhary D., Upreti M., Rath P.C., Kale R.K. Radiation induced oxidative stress. I. Studies in Ehrlich solid tumor in mice. Mol Cell Biochem 2001, 223:71-80.
39. Phillips R.M., Burger A.M., Fiebig H.H., Double J.A. Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status. NQO1 activity and the response of xenografts to mitomycin C chemotherapy in vivo (1). Biochem Pharmacol 2001, 62:1371-1377.
40. Fleming R.A., Drees J., Loggie B.W., Russell G.B., Geisinger K.R., Morris R.T., et al. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics 2002, 12:31-37.
41. Kolesar J.M., Pritchard S.C., Kerr K.M., Kim K., Nicolson M.C., McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002, 21:1119-1124.
42. Siegel D., Anwar A., Winski S.L., Kepa J.K., Zolman K.L., Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001, 59:263-268.